Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance.
See the original post:
China medical tourism--Parkinson's--stem cells therapy - Video
Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance. If you want to know more about our services, please browse the web:htttp://www.medicaltourism.hk/ or mail to us: giels-x@medicaltourism.hk firstcare-china@hotmail.com It took two months for Macie's family to put her on a plane after learning that there was a treatment available for Optic Nerve Hypoplasia.
See the original post:
China medical tourism--Optic Nerve Hypoplasia --stem cells therapy - Video
Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance.
Read the original here:
China medical tourism--Cerebral Palsy--stem cells therapy2 - Video
Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance.
Read more:
China medical tourism-Autism- Adult Stem Cell Patient - Video
Witness the miracle.
Go here to see the original:
bboy force the stem cell miracle man no longer disabled rebuilt by stemcells PART 1 thanks U of M - Video
Learn more at http://www.invitrogen.com Dr. Uma Lakshmipathy presents work on the creation of integration-free induced pluripotent stem cells at high efficiency with Sendai Virus using the CytoTune™ -iPS Sendai Reprogramming Kit. So to start with the most common method for generating iPSC is transduction of the four factors and shown here is the Yamanaka factors and after a black box in which takes anywhere between three to four weeks you end up with iPSC colonies.
Read the original here:
Dr. Uma Lakshimipathy presents Generation of Transgene-Free Induced Pluripotent Stem Cells - Video
Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance. If you want to know more about our services, please browse the web:htttp://www.medicaltourism.hk/ or mail to us: giels-x@medicaltourism.hk firstcare-china@hotmail.com Joe Leone never thought he'd go to China.
Read the rest here:
China medical tourism--Ataxia Multiple System Atrophy--stem cell therapy - Video
Indian scientists have for the first time coaxed ordinary cells to behave like cells of the heart muscle. Stem cell research is making big inroads in India and experts at the Indian Institute of Science, Bangalore have been able to recreate the way muscles of the heart behave.
See the original post:
New high in stem cell research: Mimicking the heart in a lab - Video
Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance
Go here to read the rest:
China medical tourism--spinal cord injury--stem cells therapy - Video
Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance.
Here is the original post:
China medical tourism--glaucoma--stem cells therapy - Video
Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance
View post:
China medical tourism--Austin--stem cells therapy - Video
(HealthDay News) -- Men are less willing than women to be screened for cancer, even though men have higher cancer death rates, a new study shows.
Researchers conducted a telephone survey of nearly 1,150 adults in New York City, Baltimore, and San Juan, Puerto Rico, who answered questions from the Cancer Screening Questionnaire. Most of the participants were aged 30 to 59, and 35 percent of them were men.
"This study examined beliefs and attitudes held by men and women about cancer screening. Our aim was to gain insight for improving existing cancer health promotion practices," study corresponding author Jenna Davis, of the department of health outcomes and behavior at the Moffitt Cancer Center in Tampa, Fla., said in a center news release.
"Our findings indicate that there is a need for better health and cancer screening promotion among men," she said.
The researchers suggested several reasons why men are less willing than women to undergo cancer screening: most cancer awareness campaigns in the media are for women's breast cancer; there is a lack of government-sponsored men's cancer awareness campaigns; and studies indicate that women see their primary care doctor more often than men. Read more...
Cardiofy Heart Care Supplement
The $3 billion California stem cell agency should shut its doors when its cash runs out in about six years and turn over development of stem cell therapies to industry and academe, the San Jose Mercury News said in an editorial on Saturday.
The piece in the leading newspaper in California's Silicon Valley was headlined, "Stem Cell Institute Should Take a Bow (Out)."
The newspaper wrote,
"This state is in financial crisis with no full recovery in sight. Bankrolling the next phase of research would come at the expense of other critical state services, including public education, that are state government's core mission and already are starved by budget cuts. It would be a mistake to pile more debt onto the state's already heavy bond obligations, which are paid off from the same general fund that pays for schools and other services. Medical research is important, but it is not at the heart of state government's mission. Bond measures now need to deal with water supplies and other looming crises."
The editorial said CIRM has provided a "strong foundation from which universities and companies can move toward cures."
But the newspaper concluded,
"Cures remain elusive -- there is never a guarantee with scientific research -- but the 10-year start voters approved was meant to be just that. The promise of stem cell treatments now must be kept alive with funding from industry, academic institutions and private foundations and philanthropists."
The editorial comes as the seven-year-old agency is driving to turn research into therapies that can actually be used in treatments. At the same time, CIRM is considering asking California voters to approve another multibillion bond measure in the next few years, a proposal that seems to be fresh news to many in the media.
The San Jose newspaper covered the stem cell agency with some detail in its first year of operation. In the last few years, however, the paper's coverage has been all but non-existent, like most of the news media in California.
Earlier this month, the paper published an overview of the agency, which highlighted the discussions by former CIRM Chairman Bob Klein about another bond issue, along with the fact that the cures promised by the campaign of 2004 have not materialized. The proposed bond issue is old news for most persons who have followed CIRM; the plan has been around publicly for more than a year. But the call for more cash comes a surprise to many of in the media. And to the public. So it is likely to pop up again as other news outlets re-visit the agency from time to time.
The presence of another electoral campaign also imposes a different sort of burden on CIRM – something quite removed from such matters as the basic biology of stem cells. It means that the stem cell agency's endeavors are being evaluated in a political context, which involves such questions as whether its actions are designed to generate the millions in campaign contributions necessary to win a statewide election or whether it is neglecting valuable research for something that will instead generate a high profile result for the benefit of the campaign but not add much to the science.
It is all part of tactics and strategy involved in the "communications war" that CIRM Chairman Jonathan Thomas discussed with CIRM board members last June in his bid to win election to his post.
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
Advanced Cell Technology, which has unsuccessfully sought funding several times from the $3 billion California stem cell agency, drew some attention today in a piece in a Massachusetts newspaper.
The Worcester Telegram took a look at the firm, headquartered in Santa Monica, Ca., with labs in Marlboro, Mass., in the wake of Geron's departure from hESC research. The move left ACT as the only firm in the country with an hESC trial and perhaps with a better shot at CIRM funding.
Reporter Lisa Eckelbecker wrote,
"Advanced Cell, publicly traded since 2005, has spent years developing its technologies. The company brings in little revenue and has an accumulated deficit of $180.9 million. About 1.6 billion shares of Advanced Cell common stock is outstanding, a result of numerous financings over the years. It trades for about 10 cents a share on the Over-the-Counter Bulletin Board, an electronic exchange for small companies. No analysts from major Wall Street banks report on the company.
"The company's treatment for Stargardt's macular dystrophy and dry age-related macular degeneration — the treatment that required (a) mountain of paperwork before the FDA — first went into the eyes of patients in July in Los Angeles. The retinal pigment epithelial cells, generated from embryonic stem cells, were developed to slow the progression of the eye disorders, which can lead to blindness."
ACT moved its headquarters to California following the passage of Prop. 71 in 2004, the ballot initiative that created the California stem cell agency. The company said at the time it expected to "gain significant momentum by being able to take advantage of a favorable environment for funding."
ACT initially landed in Alameda, Ca., but has since moved to Southern California. Its official opening in 2006 in Alameda was attended by the state treasurer and at least one CIRM official, according to the company. The firm has never secured funding from the stem cell agency, which does not release the names of rejected applicants. However, the California Stem Cell Report carried an item in 2008 that pointed out that a researcher for ACT complained publicly about a reviewer's conflict of interest in connection with an ACT application(see here and here). At the time, Robert Klein, then CIRM chairman, brushed off the complaint. The journal Nature has also reported that ACT has applied unsuccessfully several times for CIRM awards.
It is a fair bet that ACT was an initial applicant in the round that provided funding to Geron last spring. However, by the time Geron's application went to the full CIRM board, the other applicants had withdrawn – the first time such an event had occurred at CIRM.
Since Geron pulled out of the hESC business last month, it is likely that ACT and CIRM have opened fresh discussions, given their mutual interest in producing a stem cell therapy. CIRM also has a new chairman who is familiar with ACT. After Geron was awarded its $25 million loan from CIRM last May, the agency's board elected as chairman a Los Angeles bond financier, Jonathan Thomas, who led an early round of financing for ACT in 2000. Thomas last summer sold his remaining 17,046 shares in ACT for $3,239. Thomas said he had a "significant loss" on the sale but did not disclose the amount.
Geron's flight from hESC and ACT's perserverance come as the stem cell agency is pushing aggressively to drive research into the clinic. Plus CIRM needs tangible results that voters can understand if CIRM is win ballot-box approval for continued funding in the next few years. The agency will run out of cash in about 2017 and is considering mounting a campaign for another multibillion bond issue.
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
(HealthDay News) -- Men are less willing than women to be screened for cancer, even though men have higher cancer death rates, a new study shows.
Researchers conducted a telephone survey of nearly 1,150 adults in New York City, Baltimore, and San Juan, Puerto Rico, who answered questions from the Cancer Screening Questionnaire. Most of the participants were aged 30 to 59, and 35 percent of them were men.
"This study examined beliefs and attitudes held by men and women about cancer screening. Our aim was to gain insight for improving existing cancer health promotion practices," study corresponding author Jenna Davis, of the department of health outcomes and behavior at the Moffitt Cancer Center in Tampa, Fla., said in a center news release.
"Our findings indicate that there is a need for better health and cancer screening promotion among men," she said.
The researchers suggested several reasons why men are less willing than women to undergo cancer screening: most cancer awareness campaigns in the media are for women's breast cancer; there is a lack of government-sponsored men's cancer awareness campaigns; and studies indicate that women see their primary care doctor more often than men. Read more...
Cardiofy Heart Care Supplement
The $3 billion California stem cell agency should shut its doors when its cash runs out in about six years and turn over development of stem cell therapies to industry and academe, the San Jose Mercury News said in an editorial on Saturday.
The piece in the leading newspaper in California's Silicon Valley was headlined, "Stem Cell Institute Should Take a Bow (Out)."
The newspaper wrote,
"This state is in financial crisis with no full recovery in sight. Bankrolling the next phase of research would come at the expense of other critical state services, including public education, that are state government's core mission and already are starved by budget cuts. It would be a mistake to pile more debt onto the state's already heavy bond obligations, which are paid off from the same general fund that pays for schools and other services. Medical research is important, but it is not at the heart of state government's mission. Bond measures now need to deal with water supplies and other looming crises."
The editorial said CIRM has provided a "strong foundation from which universities and companies can move toward cures."
But the newspaper concluded,
"Cures remain elusive -- there is never a guarantee with scientific research -- but the 10-year start voters approved was meant to be just that. The promise of stem cell treatments now must be kept alive with funding from industry, academic institutions and private foundations and philanthropists."
The editorial comes as the seven-year-old agency is driving to turn research into therapies that can actually be used in treatments. At the same time, CIRM is considering asking California voters to approve another multibillion bond measure in the next few years, a proposal that seems to be fresh news to many in the media.
The San Jose newspaper covered the stem cell agency with some detail in its first year of operation. In the last few years, however, the paper's coverage has been all but non-existent, like most of the news media in California.
Earlier this month, the paper published an overview of the agency, which highlighted the discussions by former CIRM Chairman Bob Klein about another bond issue, along with the fact that the cures promised by the campaign of 2004 have not materialized. The proposed bond issue is old news for most persons who have followed CIRM; the plan has been around publicly for more than a year. But the call for more cash comes a surprise to many of in the media. And to the public. So it is likely to pop up again as other news outlets re-visit the agency from time to time.
The presence of another electoral campaign also imposes a different sort of burden on CIRM – something quite removed from such matters as the basic biology of stem cells. It means that the stem cell agency's endeavors are being evaluated in a political context, which involves such questions as whether its actions are designed to generate the millions in campaign contributions necessary to win a statewide election or whether it is neglecting valuable research for something that will instead generate a high profile result for the benefit of the campaign but not add much to the science.
It is all part of tactics and strategy involved in the "communications war" that CIRM Chairman Jonathan Thomas discussed with CIRM board members last June in his bid to win election to his post.
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
Advanced Cell Technology, which has unsuccessfully sought funding several times from the $3 billion California stem cell agency, drew some attention today in a piece in a Massachusetts newspaper.
The Worcester Telegram took a look at the firm, headquartered in Santa Monica, Ca., with labs in Marlboro, Mass., in the wake of Geron's departure from hESC research. The move left ACT as the only firm in the country with an hESC trial and perhaps with a better shot at CIRM funding.
Reporter Lisa Eckelbecker wrote,
"Advanced Cell, publicly traded since 2005, has spent years developing its technologies. The company brings in little revenue and has an accumulated deficit of $180.9 million. About 1.6 billion shares of Advanced Cell common stock is outstanding, a result of numerous financings over the years. It trades for about 10 cents a share on the Over-the-Counter Bulletin Board, an electronic exchange for small companies. No analysts from major Wall Street banks report on the company.
"The company's treatment for Stargardt's macular dystrophy and dry age-related macular degeneration — the treatment that required (a) mountain of paperwork before the FDA — first went into the eyes of patients in July in Los Angeles. The retinal pigment epithelial cells, generated from embryonic stem cells, were developed to slow the progression of the eye disorders, which can lead to blindness."
ACT moved its headquarters to California following the passage of Prop. 71 in 2004, the ballot initiative that created the California stem cell agency. The company said at the time it expected to "gain significant momentum by being able to take advantage of a favorable environment for funding."
ACT initially landed in Alameda, Ca., but has since moved to Southern California. Its official opening in 2006 in Alameda was attended by the state treasurer and at least one CIRM official, according to the company. The firm has never secured funding from the stem cell agency, which does not release the names of rejected applicants. However, the California Stem Cell Report carried an item in 2008 that pointed out that a researcher for ACT complained publicly about a reviewer's conflict of interest in connection with an ACT application(see here and here). At the time, Robert Klein, then CIRM chairman, brushed off the complaint. The journal Nature has also reported that ACT has applied unsuccessfully several times for CIRM awards.
It is a fair bet that ACT was an initial applicant in the round that provided funding to Geron last spring. However, by the time Geron's application went to the full CIRM board, the other applicants had withdrawn – the first time such an event had occurred at CIRM.
Since Geron pulled out of the hESC business last month, it is likely that ACT and CIRM have opened fresh discussions, given their mutual interest in producing a stem cell therapy. CIRM also has a new chairman who is familiar with ACT. After Geron was awarded its $25 million loan from CIRM last May, the agency's board elected as chairman a Los Angeles bond financier, Jonathan Thomas, who led an early round of financing for ACT in 2000. Thomas last summer sold his remaining 17,046 shares in ACT for $3,239. Thomas said he had a "significant loss" on the sale but did not disclose the amount.
Geron's flight from hESC and ACT's perserverance come as the stem cell agency is pushing aggressively to drive research into the clinic. Plus CIRM needs tangible results that voters can understand if CIRM is win ballot-box approval for continued funding in the next few years. The agency will run out of cash in about 2017 and is considering mounting a campaign for another multibillion bond issue.
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
see http://www.cellmedicine.com
Read more here:
Stem Cell Therapy for Multiple Sclerosis Stimulates IDO - Video
Mr. Kim had cerebral hemorrhage seven years ago.
Read more:
63 year old stroke victim was greatly improved through stem cell therapy - Video
John Lawson Cullison, Jr., an artist lost his ability to paint due to the effects of arthritis. This incurable condition is due to the degeneration in cartilage tissue and symptoms include: pain, tenderness in the joints, stiffness, loss of flexibility, bone spurs and severe swelling. Pain management and joint replacement surgery are the typical means to treating this condition
Read more:
RNL BIO brings an artist his normal life back from severe rheumatoid. by stem cell therapy - Video
